

# Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients?

Sahbudin, Ilfita; Singh, Ruchir; Trickey, Jen; Baranskaya, Aliaksandra; Tracy, Alexander; Raza, Karim; Filer, Andrew; Jowett, Sue; Boonen, Annelies

DOI:  
[10.1093/rap/rkad040](https://doi.org/10.1093/rap/rkad040)

License:  
Creative Commons: Attribution (CC BY)

*Document Version*  
Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*  
Sahbudin, I, Singh, R, Trickey, J, Baranskaya, A, Tracy, A, Raza, K, Filer, A, Jowett, S & Boonen, A 2023, 'Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients?', *Rheumatology Advances in Practice*, vol. 7, no. 2, rkad040. <https://doi.org/10.1093/rap/rkad040>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Clinical science

# Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients? A systematic review

Ifिता Sahbudin <sup>1,2,\*</sup>, Ruchir Singh <sup>1,2,3,†</sup>, Jeanette Trickey<sup>1,2</sup>, Aliaksandra Baranskaya<sup>1,2</sup>, Alexander Tracy<sup>1,2</sup>, Karim Raza<sup>1,2,3</sup>, Andrew Filer<sup>1,2</sup>, Sue Jowett<sup>4</sup>, Annelies Boonen <sup>5,6</sup>

<sup>1</sup>Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

<sup>2</sup>NHRR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

<sup>3</sup>Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, UK

<sup>4</sup>Health Economics Unit, Institute for Applied Health Research, University of Birmingham, Birmingham, UK

<sup>5</sup>Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

<sup>6</sup>Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands

\*Correspondence to: Ifिता Sahbudin, Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK. E-mail: i.sahbudin@bham.ac.uk

<sup>†</sup>I.S. and R.S. contributed equally.

## Abstract

**Objective:** Early treatment of RA improves clinical outcomes; however, the impact on health economic outcomes is unclear. This review sought to investigate the relationship between symptom/disease duration and resource utilization/costs and the responsiveness of costs following RA diagnosis.

**Methods:** A systematic search was performed on Pubmed, EMBASE, CINAHL and Medline. Studies were eligible if patients were DMARD-naïve and fulfilled 1987 ACR or 2010 ACR/EULAR RA classification criteria. Studies had to report symptom/disease duration and resource utilization or direct/indirect costs as health economic outcomes. The relationships between symptom/disease duration and costs were explored.

**Results:** Three hundred and fifty-seven records were identified in a systematic search; nine were eligible for analysis. The mean/median of symptom/disease duration in studies ranged between 25 days and 6 years. Annual direct costs of RA following diagnosis showed a U-shaped distribution in two studies. Longer symptom duration before starting a DMARD (>180 days) was associated with lower health-care utilization in the first year of RA diagnosis in one study. Annual direct and indirect costs 6 months before RA diagnosis were higher in patients with shorter symptom duration (<6 months) in one study. Given the clinical and methodological heterogeneities, the association between symptom/disease duration and costs after diagnosis was not computed.

**Conclusion:** The association between symptom/disease duration at the time of DMARD initiation and resource utilization/cost in patients with RA remains unclear. Health economic modelling with clearly defined symptom duration, resource utilization and long-term productivity is vital to address this evidence gap.

## Lay Summary

What does this mean for patients?

We studied the extent to which the cost of health care varies depending on how quickly patients with rheumatoid arthritis (RA) receive treatment after diagnosis. This is important to allow long-term financial planning within the health-care service. This is a systematic review study, which means we collect information from published papers that meet a set of criteria to see whether there is a clear pattern emerging across multiple papers. In this study, we selected papers that included patients with a diagnosis of RA and with no previous treatment for their RA. We then studied whether there is any clear link between the delay in starting treatment for RA and costs of treating RA. In two selected studies, the costs of RA treatment (e.g. medication costs, consultation costs) showed a U-shaped distribution; that means costs were high in the initial years after starting treatment, then dropped before subsequently rising again. It was not possible to assess further whether there is a clear link between the delay in starting treatment for RA and costs of treating RA, because each study used different criteria to assess treatment delay and costs of treatment. Therefore, this study highlights that there is a need for further economic modelling studies in RA.

**Keywords:** RA, early diagnosis, direct/indirect costs, health economic outcomes

Received: 29 November 2022. Accepted: 12 March 2023

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

**Key messages**

- The association between symptom/disease duration before DMARD initiation and health economic outcomes in RA is unclear.
- Clinical and methodological heterogeneities impede direct comparison of health economic outcomes across RA studies.
- Longitudinal studies with defined symptom duration and long-term RA-associated costs will address this research question.

**Introduction**

The impact of early treatment on clinical outcomes in RA is well reported [1]. However, the impact of early treatment on health economic outcomes is less clear. Patients with RA treated with intensive DMARD were more likely to stay in the workforce long term [2, 3]. This might result long term in overall lower indirect costs (i.e. lower loss of productivity). However, diagnostic decisions are vulnerable to false-positive and false-negative results. The consequence of over-diagnosis and over-treatment might lead to overall higher direct costs (i.e. higher medical costs) in the longer run, which might offset the cost savings made from improved productivity. Therefore, long-term economic diagnostic and treatment decision models are required to inform the optimal threshold for diagnostic/treatment decisions from an economic perspective. This will facilitate the estimation of long-term RA-related costs.

Therefore, as a first step, the relationship between symptom/diagnosis duration at the time of DMARD initiation and subsequent resource utilization/costs needs to be identified. We sought to investigate this through a systematic review of cost-of-illness and cost-effectiveness studies of DMARD-naïve RA patients.

**Methods**

The full Methods section is detailed in [Supplementary Data S1](#), available at *Rheumatology Advances in Practice* online.

**Protocol and registration**

The protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO 2017 CRD42017077593); [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42017077593](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42017077593).

**Study identification/search strategy**

PubMed, EMBASE, CINAHL and Medline electronic databases were searched up to 25 January 2023. All systematic searches were conducted using the same search terms and strategy ([Supplementary Data S2](#), available at *Rheumatology Advances in Practice* online). Additional records were identified through independent manual database searching, external sources and reference scanning of relevant retrieved full-text articles. Study selection, data extraction and quality assessment were done independently by two authors (I.S. and R.S.); discrepancies were resolved by consensus or through a third reviewer (A.Bo.). [Table 1](#) shows the PICOT framework.

**Study selection**

Study inclusion criteria were as follows: aged  $\geq 18$  years and fulfilling the 1987 ACR or 2010 ACR/EULAR RA classification criteria; DMARD-naïve; symptom/disease duration reported; cross-sectional and longitudinal study; and health

**Table 1.** PICOT framework to capture studies cost or resource utilization as an outcome by symptom or disease duration in patients with DMARD-naïve RA

|              |  |
|--------------|--|
| Population   | DMARD-naïve RA   |
| Intervention | Any DMARDs   |
| Comparator   | Any other DMARD treatment  |
| Outcome      | Direct costs<br>Medication costs<br>Indirect costs<br>Productivity costs<br>Resource use |
| Time         | Duration immediately preceding study inclusion or DMARD start or the period following it |
| Context      | Disease or symptom duration in relationship to the costs/resources                       |

PICOT: patient, intervention, comparison, outcome and time.

economic outcomes reported as costs or resource utilization. Studies excluded were studies of non-RA inflammatory arthritides and conference abstracts, systematic reviews and review articles.

**Data extraction**

The following data were extracted: study characteristics; potential determinants of RA costs; sources of resource utilization and costs; and health economic outcomes.

**Quality assessment**

The Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) checklist [4] and a modified checklist by Drummond and Jefferson [5] were used for quality assessment.


**Data synthesis and statistical analysis**

A meta-analysis/regression on the association between disease/symptom duration and costs could not be performed owing to the number of studies and methodological heterogeneity, especially in reporting of health economic outcomes. Cost data per patient per year for the reported duration in studies were recorded and summarized in a unifying currency of US Dollars 2021 after adjusting for the Purchasing Power Parity (PPP) and Consumer Price Index (CPI) 2021 [6, 7].

**Results**

Nine articles were included in this systematic review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart shows the literature search results ([Fig. 1](#)).

[Table 2](#) summarizes study characteristics, cost categories and annual costs in international USD 2021. Six papers were cost-of-illness studies [8–13] and the remainder cost-utility



**Figure 1.** PRISMA flow chart of the four searches conducted. CINAHL: The Cumulative Index to Nursing and Allied Health; EMBASE: Excerpta Medica Database; MEDLINE: Medical Literature Analysis and Retrieval System Online

studies [14–16]. Four studies were observational studies [8, 11, 13, 16] and five randomized controlled trials (RCTs) [9, 10, 12, 14, 15].

Sociodemographic and clinical characteristics of patients are summarized in [Supplementary Table S1](#), available at *Rheumatology Advances in Practice* online. Cost categories,

**Table 2.** Study characteristics, health economic outcomes and annual costs in US Dollars 2021

| Author country, year  | Objective<br>Study design<br>Study setting  | Patient characteristics<br>Symptom duration  | Outcome<br>Study perspective  | Results as resources or<br>costs by category (e.g.<br>days hospitalized) or type<br>(total health care;<br>productivity)   | Results as total resources or<br>cost in local currency at<br>time of the study   | Cost per person per year in USD 2021<br>after adjusting for purchasing power parity<br>and consumer price index 2021 (OECD, 2021) [1, 2]   |
|---|---|--|---|--|---|--|
| Luurssen-Masurel<br><i>et al.</i> [14]<br>The Netherlands, 2021 | Objective: to assess cost-effectiveness of three different initial treatments in seronegative DMARD-naïve RA patients, defined as patients from the rREACH trial with an intermediate probability of developing persistent arthritis who fulfilled RA 2010 criteria and were RF and ACPA negative at baseline<br><br>Study design: cost-utility study in the context of clinical trial of 1 year duration.<br><br>Study setting: patients recruited from eight rheumatology centres | <i>n</i> : 116<br>Female: 69.8%<br>Age (average): 54.8 years<br>Symptom duration, median (IQR): 134 (95–205) days  | Outcomes:<br>1) Incremental cost-effectiveness ratio between two of the three initial treatment strategies.<br>2) Loss of productivity per year by: friction cost approach (including productivity loss owing to presenteeism) valued at age- and sex-dependent standard costs per hour.<br><br>Study perspective:<br>1) Partial societal<br>2) Health care | Currency: Euros 2019<br>Total health-care costs by treatment strategy group per patient during 1 year of follow-up<br>mean (s.d.):<br>iMTX: 2584 (2196)<br>iHCQ: 2123 (2172)<br>iGC: 3050 (3461)<br><br>Total productivity costs by treatment strategies group<br>Mean (s.d.):<br>iMTX: 8249 (14 171)<br>iHCQ: 9085 (11 571)<br>iGC: 7453 (10 446)             | Total costs (health-care and productivity costs) by treatment strategy group per patient per year<br>Mean:<br>iMTX 3456<br>iHCQ 11 208<br>iGC 10 502  | Total health-care costs by treatment strategy group, per patient in USD 2021<br>Mean:<br>iMTX 3456<br>iHCQ 2839<br>iGC 4079<br><br>Total productivity costs by treatment strategies group in USD 2021<br>Mean:<br>iMTX 11 031<br>iHCQ 12 149<br>iGC 9967<br><br>Total costs (health-care and productivity costs) by treatment strategy groups in USD 2021:<br>Mean:<br>iMTX 14485<br>iHCQ 14 988<br>iGC 14,044 |
| Verhoeven <i>et al.</i> [15]<br>The Netherlands, 2021           | Objective: to assess cost-effectiveness of initiating TCZ ± MTX <i>vs</i> initiating MTX as treat-to-target treatment strategies over 5 years in early DMARD-naïve RA.<br><br>Study design: cost-utility study in the context of a clinical trial (2 years) and post-clinical trial follow-up (3 years).<br><br>Study setting: 21 rheumatology outpatient clinics in the Netherlands  | <i>n</i> : 317<br>Female, <i>n</i> (%):<br>TCZ+MTX 65 (61)<br>TCZ 78 (76)<br>MTX 69 (64)<br><br>Age, years, median (IQR):<br>TCZ+MTX 53.0 (46.0–60.0)<br>TCZ 55.0 (47.0–63.0)<br>MTX 53.0 (44.5–62.0)<br><br>Symptom duration, days, median (IQR):<br>TCZ+MTX 24.5 (16.0–41.5)<br>TCZ 25.5 (18.0–45.0)<br>MTX 27.0 (15.0–46.0) | Outcomes:<br>1) Incremental cost-effectiveness ratios between two treatment strategies.<br>2) Productivity loss costs by human capital approach and friction cost approach.<br><br>Study perspective:<br>1) Health care<br>2) Partial societal  | Currency: Euros 2017<br>Costs (€, rounded to the nearest hundred) by treatment strategies group, means<br><br>Medication costs:<br>TCZ + MTX 17 900<br>TCZ 18 400<br>MTX 4400<br><br>Direct health-care costs (excluding medication costs):<br>TCZ+MTX 6100<br>TCZ 7200<br>MTX 7000<br><br>Indirect non-health-care-related costs:<br>TCZ+MTX 1100<br>TCZ 1600 | Total costs (health-care and productivity costs) by treatment strategy group (in euros 2017)<br>Mean per patient per year, at end of year 1<br><br>Direct healthcare-related costs:<br>TCZ+MTX 6100<br>TCZ 7200<br>MTX 7000<br><br>Total medication costs:<br>TCZ + MTX 17 900<br>TCZ 18 400<br>MTX 4400<br><br>Total productivity costs loss using human capital approach:<br>TCZ+MTX 6700 | Total costs (health-care and productivity costs) by treatment strategies group (in USD 2021)<br>Mean per year, at end of year 1<br><br>Direct health-care costs (excluding medication costs):<br>TCZ + MTX 15 546<br>TCZ 18 350<br>MTX 17 840<br><br>Total medication costs:<br>TCZ + MTX 45 620<br>TCZ 46 894<br>MTX 11 214<br><br>Total productivity costs loss using human capital approach:                |

(continued)

**Table 2.** (continued)

| Author country, year                               | Objective<br>Study design<br>Study setting   | Patient characteristics<br>Symptom duration  | Outcome<br>Study perspective   | Results as resources or costs by category (e.g. days hospitalized) or type (total health care; productivity)  | Results as total resources or cost in local currency at time of the study  | Cost per person per year in USD 2021 after adjusting for purchasing power parity and consumer price index 2021 (OECD, 2021) [1, 2]   |
|--|--|--|--|---|--|--|
|  |  |  |  | MTX 1500<br>Productivity costs loss using human capital approach:<br>TCZ+MTX 6700<br>TCZ 5600<br>MTX 6500<br><br>Productivity loss costs using friction cost approach:<br>TCZ+MTX 2500<br>TCZ 2300<br>MTX 2500  | TCZ 5600<br>MTX 6500<br>Total productivity loss costs using friction cost approach:<br>TCZ+MTX 2500<br>TCZ 2300<br>MTX 2500<br><br>Indirect non-health-care-related costs:<br>TCZ+MTX 1100<br>TCZ 1600<br>MTX 1500 | TCZ + MTX 17 076<br>TCZ 14 272<br>MTX 16 566<br>Total productivity loss costs using friction cost approach:<br>TCZ + MTX 6371<br>TCZ 5862<br>MTX 6371<br><br>Indirect non-health-care-related costs:<br>TCZ + MTX 2803<br>TCZ 4078<br>MTX 3823 |
| Syngle <i>et al.</i> [16]<br>India, 2017           | Objective: to assess the cost and effects of synthetic DMARDs in treatment-naïve RA patients.<br><br>Study design: cost–utility study in the context of longitudinal observational study.<br><br>Study setting: one rheumatology outpatient clinic | <i>n</i> : 98<br>Female: 86%<br>Age, mean (s.d.): 47.8 (12.3) years<br><br>Disease duration at inclusion, mean (s.d.): 5.8 (5.0) years                             | Outcome: average cost-effectiveness ratio. Cost is measured in monetary value and the effectiveness of treatment is measured as change in HAQ-DL.<br><br>Study perspective: healthcare | Currency: Indian Rupees 2017<br>Direct medical costs<br>Medication costs (average/month):<br>DMARDs 398<br>CSs 136.3<br>NSAIDs 16.66<br>Medicines to prevent adverse drug reaction 48.8<br>Monitoring costs (average/month):<br>Laboratory costs 354<br>Radiology 24.3<br>Ophthalmology 5.97<br>Doctor consultation charges (average/month): 10 | Average direct medical costs per RA prescription per month in Indian Rupees 2017: 997<br><br>Average direct medical cost per patient per year in Indian Rupees (2017): 11 965                                      | Total health-care (drugs and monitoring) cost per patient per year adjusted to USD 2021: 1008  |
| Kuijper <i>et al.</i> [8]<br>The Netherlands, 2014 | Objective: comparison of disease burden between RA patients and arthralgia in an early arthritis cohort.<br><br>Study design: inception cohort study.<br><br>Study setting: patients recruited at first consultation with general practitioners or | <i>n</i> : 244 <sup>c</sup><br>Female: 68%<br>Age, mean (s.d.): 54 (13.7) years<br>Symptom duration at study inclusion <sup>d</sup> , mean (IQR): 103 (7–373) days | Outcome:<br>Health-care utilization (number of visits):<br>GP<br>Specialist<br>Physiotherapist<br>Alternative<br><br>Study perspective: health care                                    | Health-care utilization At baseline (number of visits):<br>GP 2.8 visits<br>Specialist 1.4<br>Physiotherapist visits/5 = 0.5<br>Alternative visits 0.1<br>All visits 4.7<br><br>At 6-month time point:<br>GP 0.5<br>Specialist 2.6  | Total health-care utilization units for the first 12 months post DMARD initiation:<br>6.5 visits per patient per year  | Monetary value not reported  |

(continued)

Table 2. (continued)

| Author country, year                                     | Objective<br>Study design<br>Study setting  | Patient characteristics<br>Symptom duration  | Outcome<br>Study perspective   | Results as resources or costs by category (e.g. days hospitalized) or type (total health care; productivity)  | Results as total resources or cost in local currency at time of the study  | Cost per person per year in USD 2021 after adjusting for purchasing power parity and consumer price index 2021 (OECD, 2021) [1, 2] |
|--|---|--|--|---|--|--|
|  | Rheumatology outpatient of five hospitals.  |  |  | Physiotherapist visits/5 = 0.6<br>Alternative 0.1<br>All visits 3.9<br>At 12-month time point:<br>GP 0.4<br>Specialist 1.6<br>*Physiotherapist visits/5 = 0.5<br>Alternative 0.1<br>All visits 2.6  |  |  |
| Puolakka <i>et al.</i> [9]<br>Finland, 2009 <sup>c</sup> | Objective: to assess the impact of HAQ on productivity loss in early RA patients.<br><br>Study design: data collection at 5-year follow-up in an extension of a randomized controlled trial.<br><br>Study setting: 18 recruitment centres for FIN-RACo Trial. | HAQ group 1<br><i>n</i> : 13<br>Female: 31%<br>Age, mean (s.d.): 45 (9) years<br><br>Disease duration at inclusion, mean (s.d.): 11 (9) months<br>HAQ group 2<br><i>n</i> : 65<br>Female: 62%<br>Age, mean (s.d.): 45 (9) years<br><br>Disease duration at inclusion, mean (s.d.): 8 (5) months<br>HAQ group 3<br><i>n</i> : 65<br>Female: 68%<br>Age, mean (s.d.): 47 (4) years<br><br>Disease duration at inclusion, mean (s.d.): 8 (5) months<br>HAQ group 4<br><i>n</i> : 16<br>Female: 69%<br>Age: 50 (s.d. 9)<br><br>Disease duration at inclusion, mean (s.d.): 10 (7) months | Outcome:<br>1) Work disability days<br>2) Indirect costs <sup>g</sup> ;<br>Loss of productivity per year by:<br>i) Human capital approach<br>ii) Friction cost approach<br><br>Study perspective: partial societal | Values are given as mean per patient per year (95% CI)<br>HAQ group 1<br>Work disability (days per year): 34 (5–145)<br>Loss of productivity per year (HCA), euros: 440 (137–896)<br>Loss of productivity per year (FCA), euros: 353 (118–712)<br><br>HAQ group 2<br>Work disability (days per year): 33 (19–57)<br>Loss of productivity per year (HCA), euros: 2704 (1457–4606)<br>Loss of productivity per year (FCA), euros: 1360 (963–1870)<br><br>HAQ group 3:<br>Work disability (days per year): 146 (112–185)<br>Loss of productivity per year (HCA), euros: 12 072 (8788–15 758)<br>Loss of productivity per year (FCA), euros: 2452 (1902–3153)<br><br>HAQ group 4:<br>Work disability (days per year): 272 (194–328)<br>Loss of productivity per year (HCA), euros: 23 985 (16 448–33 141)<br>Loss of productivity per year (FCA), euros: 3662 (2518–5237) | Loss of productivity costs per patient per year in USD 2021, mean:<br>HCA 736<br>FCA 590<br><br>Loss of productivity costs per patient per year in USD 2021, mean:<br>HCA 4523<br>FCA 2275<br><br>Loss of productivity costs per year in USD 2021, mean:<br>HCA 20 191<br>FCA 4101<br><br>Loss of productivity costs per year in USD 2021, mean:<br>HCA 40 116<br>FCA 6125 |  |

(continued)

**Table 2.** (continued)

| Author country, year                                   | Objective<br>Study design<br>Study setting   | Patient characteristics<br>Symptom duration  | Outcome<br>Study perspective  | Results as resources or costs by category (e.g. days hospitalized) or type (total health care; productivity)   | Results as total resources or cost in local currency at time of the study  | Cost per person per year in USD 2021 after adjusting for purchasing power parity and consumer price index 2021 (OECD, 2021) [1, 2]   |
|--|--|--|---|--|--|--|
| Verstappen <i>et al.</i> [10]<br>The Netherlands, 2004 | Objective: to estimate annual direct costs and their predictors in patients with four disease duration groups.<br><br>Study design: cost-of-illness study within open-label extension of two randomized clinical trials.<br><br>Patients in RCT 1 were randomly assigned to one of four treatment regimes <sup>b</sup> .<br><br>Patients in RCT 2 were allocated to either intensive or conservative MTX treatment.<br><br>(Questionnaires were sent out in October 1999 and April 2000.)<br><br>Study setting: seven rheumatology outpatient clinics in the Utrecht region <sup>a</sup> | <i>n</i> : 509<br><i>n</i> : 96 from group with disease duration follow-up: 0 to ≤2 years<br>Female: 73%<br>Age, mean (s.d.): 54 (15) years<br>Disease duration at inclusion, mean (s.d.): 0.9 (0.6) years | Outcome:<br>Direct medical costs<br>Consultations with health-care workers<br>Admissions to health-care facilities (hospital, including surgical procedures, rehabilitation centre, nursing home)<br>Medication<br>Laboratory tests<br>Devices to perform daily activities and adaptations at home<br>Alternative medicine<br>Other costs<br><br>Study perspective: Health care and patient | Currency: Euros; publication year 2004.<br>Mean (median) (range):<br>Consultation with healthcare workers 1448 (1433) (0–8090)<br>Admission to care facilities 1391 (7283) (0–57 930)<br>RA-related medication 478 (406) (0–2895)<br>Devices and adaptations 963 (2247) (0–15 571)<br>Laboratory tests 296 (131) (75–975)<br>Alternative therapies 103 (338) (0–6080)<br>Total extra costs 554 (1094) (0–6080) | Direct costs per patient per year<br>Mean (median) (range): 5235 (2923) (570–74 080)   | Mean of total direct costs per patient per year in USD 2021: 14 613<br><br>Median of total direct costs per patient per year in USD 2021: 8159   |
| Merkesdal <i>et al.</i> [11]<br>Germany, 2001          | Objective: to assess the extent of indirect costs, changes in cost components, and correlations between changes in cost and social, clinical and occupational variables within the first 3 years of RA.<br><br>Study design: longitudinal prospective observational study.<br><br>Study setting: four rheumatology centres   | <i>n</i> : 133<br>Female: 63<br>Age, mean (s.e.m.): 47 (0.8) years<br>Disease duration at inclusion, mean (s.e.m.): 7 (0.3) months   | Outcome: indirect costs<br>Loss of productivity owing to:<br>sick leave<br>work disability<br>other work loss<br><br>Study perspective: partial societal  | Currency: US dollars for the period 1994–1996<br>Mean (s.e.m.):<br>Sick leave<br>Time 0–time 2 10 530 (990)<br>Time 2–time 3 2520 (580)<br>Time 0–time 3 7640 (740)<br>Work disability<br>Time 0–time 2 1210 (360)<br>Time 2–time 3 4570 (960)<br>Time 0–time 3 2520 (550)   | Currency: US dollars for the period 1994–1996<br>Total productivity costs (sick leave, work disability and other work loss)<br>Mean (s.e.m.):<br>Time 0–time 2 12 580 (1030)<br>Time 2–time 3 9890 (1210)<br>Time 0–time 3 11 750 (1120) | Cost per person per year in USD 2021 after adjustment for purchasing power parity and Consumer Price Index 2021<br>Total productivity costs (sick leave, work disability and other work loss)<br>Mean:<br>Time 0–time 2 20 180<br>Time 2–time 3 15 865<br>Time 0–time 3 18 848 |

(continued)



Table 2. (continued)

| Author country, year                          | Objective<br>Study design<br>Study setting  | Patient characteristics<br>Symptom duration  | Outcome<br>Study perspective  | Results as resources or costs by category (e.g. days hospitalized) or type (total health care; productivity)   | Results as total resources or cost in local currency at time of the study  | Cost per person per year in USD 2021 after adjusting for purchasing power parity and consumer price index 2021 (OECD, 2021) [1, 2]   |
|---|---|--|---|--|--|--|
|   |   |  |   | Other work loss<br>Time 0–time 2 840 (370).<br>Time 2–time 3 2800 (780).<br>Time 0–time 3 1590 (480).<br>Definition of time points:<br>Time 0 = joint swelling onset<br>Time 2 = 12 months from study enrolment<br>Time 3 = 24 months from study enrolment   |  |  |
| Newhall-Perry <i>et al.</i> [13]<br>USA, 2000 | Objective: to examine direct and indirect costs of RA during the first year of disease.<br><br>Study design: longitudinal observational study.<br><br>Study setting: patients recruited at 26 rheumatology centres in western USA and Mexico (3 practices are University medical centres and 23 community practices). | <i>n</i> : 150<br>Female: 80%<br>Age, mean (s.d.): 51 (13) years<br><br>Disease duration at inclusion, mean (s.d.): 5.9 (2.9) months | Outcome:<br>1) Direct costs<br>2) Indirect costs<br><br>Study perspective:<br>1) Health care (direct costs)<br>2) Partial societal (indirect costs) | Currency: US dollars 1994<br>Disease duration <6 months ( <i>n</i> = 87)<br>Mean (s.d.):<br>Direct costs per month 240 (285)<br>Medication costs: 62 (101)<br>Health-care visits: 65 (69)<br>Radiographs 65 (196)<br>Laboratory tests: 27 (26)<br>Hospitalizations: 00<br>Assistive devices: 3 (6)<br>Non-traditional treatments 1 (3)<br>In-home assistance 9 (47)<br>Outpatient procedures 8 (49)<br>Indirect costs per month 348 (567)<br>Disease duration ≥6 months<br>Mean (s.d.)<br>Direct costs per month 144 (149)<br>Medication costs: 43 (36)<br>Health-care visits 37 (28)<br>Radiographs 26 (30)<br>Laboratory tests 13 (12)<br>Hospitalizations 16 (97) | Results in local currency and year of assessment<br>Mean (s.d.):<br>Total RA costs (direct and indirect cost/month) in patients with disease duration <6 months 586 (686)<br>Total RA costs (direct and indirect cost/month) in patients with disease duration ≥6 months 332 (585) | Cost per person per year in USD 2021 after adjusting for purchasing power parity and Consumer Price Index 2021<br>Total costs (direct and indirect costs) of RA per year per patient for overall cohort, mean: 10 372<br>Direct costs per year per patient for overall cohort, mean: 4322<br>Indirect costs of per year per patient for overall cohort, mean: 6072<br>Cost by disease duration groups:<br>Indirect costs <6 months, mean: 7520<br>Indirect costs ≥6 months, mean: 4063<br>Direct costs <6 months, mean: 5186<br>Direct costs ≥6 months, mean: 3112<br>Total RA costs (direct and indirect) <6 months, mean: 12 663<br>Total RA costs (direct and indirect) ≥6 months, mean: 7174 |

(continued)

**Table 2.** (continued)

| Author country, year                                      | Objective<br>Study design<br>Study setting   | Patient characteristics<br>Symptom duration  | Outcome<br>Study perspective  | Results as resources or costs by category (e.g. days hospitalized) or type (total health care; productivity)   | Results as total resources or cost in local currency at time of the study  | Cost per person per year in USD 2021 after adjusting for purchasing power parity and consumer price index 2021 (OECD, 2021) [1, 2]   |
|---|--|--|---|--|--|--|
|   |  |  |   | Assistive devices 3 (11)<br>Non-traditional treatments 2 (9)<br>In-home assistance 3 (16)<br>Outpatient procedures 1 (5)<br>Indirect costs per month 188 (506)   |  |  |
| van Jaarsveld <i>et al.</i> [12]<br>The Netherlands, 1998 | Objective: estimation of:<br>1) Annual direct RA related costs in the first 6 years.<br>2) Sociodemographic and clinical predictors of these costs.<br><br>Study design:<br>cross-sectional data collection of direct costs for all patients recruited in RCT. [First patient in trial was enrolled 1990. Results were represented as the total group independent of the treatment arm. Study questionnaire sent in April 1996]<br><br>Study setting:<br>Six rheumatology centres in Utrecht region. | <i>n</i> : 363<br><i>n</i> : 63 from patient with symptom duration at 1 year follow-up<br>Female: 64%<br>Age, median (range): 57 (19–84) years<br>Disease duration at inclusion: 0–1 years | Outcome:<br>1) Direct medical cost:<br>Health-care workers cost<br>Days in care facilities<br>Medication<br>Medication side effects monitoring<br>Alternative medicine<br>2) Direct non-medical costs:<br>Devices and adaptations at home<br>Other costs: travel expenses, medication not provided by national health service, additional costs of energy, telephone and clothing, payments to friends for care, payment for help around the house, and other costs specified by the patients.<br>Study perspective:<br>health care and patient | Currency: Dutch florins; September 1997.<br>Direct medical costs for disease duration 0–1 year<br>Mean (s.d.) median per patient per year:<br>Total direct cost 14 455 (20 411) 7370<br>Subtotal direct medical cost <sup>f</sup> 9882 (1898) 4444<br>Consultations with health-care worker 3355 (3112) 2340<br>Days in care facilities 4620 (15 521) 0<br>Medication 1340 (682) 1170<br>Monitoring for side effects 484 (311) 416<br>Alternative medicine 83 (299) 0<br>Subtotal direct non-medical cost 4573 (8934) 2268<br>Adaptations and devices 2814 (6797) 150<br>Other costs 1759 (3101) 600 | Direct medical cost for disease duration 0–1 year<br>Mean (s.d.) median per patient per year in Dutch florins:<br>Total direct costs 14 455 (20 411) 7370<br>Subtotal direct medical cost <sup>f</sup> 9882 (1898) 4444<br>Subtotal direct non-medical cost 4573 (8934) 2268 | Cost per person per year in USD 2021 after adjusting for purchasing power parity and Consumer Price Index 2021<br>Mean (median) per patient per year in USD 2021 (at the end of year 1 of follow-up):<br>Total direct costs 24 094 (12 285)<br>Subtotal direct medical cost <sup>f</sup> 16 472 (7407)<br>Subtotal direct non-medical cost 7623 (3780) |

<sup>a</sup> Collaborating in the Utrecht RA cohort study group.  
<sup>b</sup> Pyramid, i.m. gold, MTX or HCQ.  
<sup>c</sup> *n* = 330 arthralgia patients recruited.  
<sup>d</sup> Median (range).  
<sup>e</sup> Outcome data were split into four groups based on HAQ: group 1 (HAQ = 0 at baseline and 6 months); group 2 (HAQ > 0 at baseline, 0 at 6 months); group 3 (HAQ ≥ 0 at baseline, >0 but <1.0 at 6 months); and group 4 (HAQ ≥ 0 at baseline, ≥1.0 at 6 months).  
<sup>f</sup> Subtotal of medical cost includes costs owing to contacts with health-care workers, days spent in care facilities, medication, monitoring for side effects and alternative medicine. Subtotal of non-medical direct cost includes costs of adaptations in the home, devices and other costs.  
<sup>g</sup> HCA = mean productivity per day over a 5-year follow-up was calculated for each patient and multiplied by the cumulative number of their days off work to yield the patients' loss of productivity by the HCA. FCA = estimation of loss of productivity, with the assumption that someone replaces the disabled worker after the friction period, that the initial production level is restored, and that production losses are confined to the friction period. RA-related work disability days were obtained from the official register, divided by the duration (in years) of follow-up during which the patient had not retired owing to other diseases or because of age. All final cost column states the cost per person per year in USD 2021 after adjusting for purchasing power parity and Consumer Price Index 2021.  
 GP: general practitioner; IQR: interquartile range; RCT: randomized controlled trial; TCZ: tocilizumab; USD: US dollars.

source of cost reference and results in local currency are summarized in [Supplementary Table S2](#), available at *Rheumatology Advances in Practice* online.

The symptom, disease or diagnosis duration variables reported at baseline varied. Two studies reported symptom duration [8, 14], six studies disease duration [9–13, 16] and one diagnosis duration [15]. Only one study clearly defined symptom duration: ‘first onset of joint swelling’ [11]. The remaining studies did not state the definitions of symptom, disease or diagnosis duration [8–15].

Resource utilization and cost data across studies were heterogeneous ([Table 1](#)). Three studies reported costs (i.e. monetary value) but not resource utilization [13, 15, 16]. One study reported resource utilization without monetary values [8]. Three studies reported resource utilization and costs [10, 12, 14]. Two studies reported costs data as loss of productivity costs [9, 11].

Direct medical costs were reported in six studies (two observational studies [13, 16] and four clinical trials [10, 12, 14, 15]). Two studies reported direct non-medical costs [10, 12]. Health-care utilization with no monetary value was reported in one study [8].

Loss of productivity (indirect cost) was recorded in four studies [9, 11, 14, 15]. Two studies calculated productivity loss using the human capital and friction cost approach [9, 15]. One study used only the human capital approach [11], and one study used only the friction cost approach [14].

Study perspective refers to the point of view adopted in the economic evaluations [17], i.e. who pays for the cost. Common study perspectives are the patient, health-care system or society. Three studies reported societal perspectives (i.e. health-care and productivity loss costs) [13–15]. Two studies reported a partial societal perspective (productivity loss costs) [9, 11], and two studies reported costs from the health-care perspective [8, 16]. In addition, two studies reported both health-care (direct medical costs) and patient perspectives [10, 12].

Quality assessment has been included in [Supplementary Data S3](#) and [Table S3](#), available at *Rheumatology Advances in Practice* online.

## Narrative synthesis

Luurssen-Masurel *et al.* [14] performed a cost–utility study in seronegative RA patients in the Rotterdam Early Arthritis Cohort (tREACH) trial. The median symptom duration was 134 days [interquartile range (IQR) 95–205 days]; follow-up duration was 1 year. Initial treatment strategies were MTX (iMTX) 25 mg once weekly, HCQ (iHCQ) 400 mg daily or a tapering course of oral glucocorticoids (iGC). There was no significant difference in the mean cumulative health-care costs over 1 year for treatment with iMTX, iHCQ and iGCs ([Table 2](#)). The difference in productivity costs over 1 year between the three groups was mainly attributed to different levels of presenteeism ([Table 1](#)). After adjusting for PPP and CPI 2021, mean total costs (health-care and productivity costs) by treatment strategy groups in USD 2021 were \$14 485, \$14 988 and \$14 044 for the iMTX, iHCQ and iGC groups, respectively. The association between symptom duration and health-care/productivity costs in the overall cohort or by treatment groups was not assessed.

Verhoeven *et al.* [15] reported a 5-year cost–utility analysis of an RCT comparing tocilizumab (TCZ) plus MTX or TCZ monotherapy with MTX monotherapy in DMARD-naïve

early RA patients. The median (IQR) symptom duration by treatment groups was 25 (16–42) days, 26 (18–45) days and 27 (15–46) days for the TCZ plus MTX, TCZ and MTX groups, respectively. Cumulative 5-year productivity cost loss [by human capital approach (HCA)] was highest in the TCZ plus MTX group (€51 700;  $n=106$ ) compared with the TCZ monotherapy and MTX monotherapy groups [€39 900;  $n=103$  and €46 500,  $n=108$  respectively]. Cumulative 5-year productivity cost loss (HCA) was highest in the TCZ plus MTX group (€51 700) compared with the TCZ monotherapy and MTX monotherapy groups (€39 900 and €46 500, respectively). After adjusting for PPP and CPI 2021, total direct health-care-related costs (mean) in USD 2021 at the end of year 1 were \$15 546, \$8350 and \$17 840 per patient for the TCZ plus MTX, TCZ and MTX groups, respectively. The association between symptom duration and health-care or productivity costs in the overall cohort or by treatment groups was not assessed.

Syngle *et al.* [16] reported RA-related health-care costs in a single-centre prospective observational study of 3 months in India. The study assessed the cost-effectiveness of synthetic DMARDs in DMARD-naïve RA patients [16]. The mean disease duration was 5.78 years (s.d. 4.84 years). Costs reported were the average total direct medical cost per prescription per month over the 3-month study period. This figure equates to 997.05 Indian Rupees per patient. After adjusting for PPP and CPI 2021, the average (extrapolated) annual direct medical costs at the end of year 1 in USD 2021 was \$1008 per patient. The association between disease duration and direct medical costs was not assessed.

Kuijper *et al.* [8] compared health-care utilization between arthralgia and DMARD-naïve early RA patients at baseline, 6 and 12 months in a Dutch inception observational cohort study [8]. The median symptom duration for RA patients was 103 days (range 7–373 days). Use of DMARDs was not reported. A longer (>180 days) *vs* short symptom duration (90–180 days) at baseline was associated with lower levels of health-care utilization over 12 months [Incidence Ratio Rate of 0.65 (95% CI 0.50, 0.85,  $P=0.002$ )]. The mean number of visits to medical specialists peaked at 6 months in the RA group ([Table 2](#)). However, a decrease in overall health-care visits (i.e. general practitioner, medical specialist, physiotherapist and alternative health practitioner visits) was observed following diagnosis ([Table 2](#)). No monetary value was reported in this study. In summary, longer symptom duration (>180 days) was associated with lower health-care utilization over the first year of diagnosis.

Puolakka *et al.* [9] assessed the impact of the Stanford Health Questionnaire (HAQ) index on loss of productivity in early DMARD-naïve RA patients in the Finnish RA Combination Therapy (FIN-RACo) open-label extension clinical trial in Finland. Patients were randomized to either a combination of three DMARDs (SSZ, MTX and HCQ) and prednisolone, or a single DMARD with or without prednisolone [9] for 2 years and were followed up for 5 years. The mean disease duration across the four HAQ groups was between 8 and 11 months. In the overall cohort and over 5 years, the annual mean loss of productivity per patient was €8344 (95% CI 6516, 10 480) by the HCA and €1928 (95% CI 1567, 2298) by the friction cost approach (FCA). Functional capacity was assessed by HAQ at baseline and 6 months. The HAQ score after 6 months of treatment, but not the level of HAQ at baseline, predicted productivity costs

in the overall cohort. Over 5 years, the top HAQ quartile had the highest work disability days per year [mean 273 days (95% CI 194, 328)], compared with the lowest HAQ quartile [mean 34 days (95% CI 5, 145)]. After adjusting for PPP and CPI 2021, the annual mean loss of productivity in USD 2021 in the top quartile group was \$40 116 by the HCA method and \$6125 by the FCA method. No analysis was performed to assess the impact of disease duration on costs in the overall cohort or by HAQ groups.

Verstappen *et al.* [10] assessed the total annual direct costs over different follow-up periods after first DMARD in Dutch patients with RA and identified sociodemographic, clinical and psychological predictors of high costs in two RCTs. Patients in the first RCT were randomized into one of four treatment arms [pyramid (NSAID followed by a DMARD for treatment failure), i.m. gold, MTX or HCQ]. Patients from the second RCT were randomized into intensive *vs* conventional MTX regimes. In this study, costs data were classified into three groups with increasing follow-up duration after diagnosis (0 to  $\leq 2$  years, 2 to  $\leq 6$  years and 6 to  $\leq 10$  years). In addition, RA patients with disease duration  $\geq 10$  years from the Utrecht RA Cohort study group were included to capture costs data for patients with longstanding RA. There was a significant difference in annual direct costs between the four groups. The median annual direct costs per patient showed a U-shaped distribution, i.e. costs were high for patients with follow-up duration 0 to  $\leq 2$  years (€2923) and reduced after 2–6 years (€1967), but increased again for  $\geq 10$  years follow-up duration (€3778). Data from the group with the shortest follow-up duration were extracted for Table 1. Functional disability (HAQ) was the most important variable associated with high costs after adjusting for sociodemographic, clinical and psychological variables. After adjusting for PPP and CPI 2021, the annual mean (median) of total direct costs per patient in USD 2021 was \$14 613 (\$8159). The annual direct costs of early RA follow a U-shaped distribution over 10 years following the start of DMARDs. No analysis was performed to assess the impact of disease duration at baseline on costs in the overall cohort.

Merkesdal *et al.* [11] reported the magnitude of indirect costs, changes within cost components and the correlation between changes in cost and social, clinical and occupational variables within first 3 years for DMARD-naïve RA patients in a multicentre observational study in Germany. The average indirect cost in early RA at the 24-month follow-up was high; \$11 750 per person-year (US dollars for the period 1994–1996), which related to 126 days of loss of productivity. Loss of productivity owing to sick leave accounted for 84% of overall loss of productivity (sick leave, work disability and other work loss) between the onset of disease and the end of the first year after study enrolment, compared with only 25% at the end of the second year of the study enrolment [11]. After adjusting for PPP and CPI 2021, the mean costs associated with total sick leave, work disability and other work losses in USD 2021 were \$20 180 after 12 months of follow-up and \$18 848 per person per year at the 24-month follow-up time point. The relationship between disease duration and loss of productivity was not reported.

Newhall-Perry *et al.* [13] assessed the direct and indirect costs of seropositive RA patients 6 months before diagnosis in a longitudinal observational study at rheumatology centres in the western USA and Mexico. All patients were DMARD-naïve and had clinically active disease, with at least nine

tender and six swollen joints and a positive RF. Patients were classified as disease duration of  $< 6$  months ( $n = 87$ ) and  $\geq 6$  months ( $n = 63$ ). At baseline, the mean total direct costs and indirect costs of RA 6 months before diagnosis were \$200 per month and \$281 per month in 1994 USD, respectively. The total direct costs of RA [mean (s.d.)] 6 months before diagnosis in patients with disease duration  $< 6$  months compared with  $\geq 6$  months were \$240/month  $\pm$  \$285 and \$144/month  $\pm$  \$149,  $P < 0.001$ , respectively. Likewise, indirect costs were higher in patients with a disease duration  $< 6$  months as opposed to  $\geq 6$  months (\$348/month  $\pm$  \$567 *vs* \$188/month  $\pm$  \$506;  $P < 0.005$ ) at baseline. After adjusting for PPP and CPI 2021, the annual mean total direct and indirect costs 6 months before diagnosis per person in USD 2021 were \$12 663 for  $< 6$  months and \$7174 for  $\geq 6$  months groups. Overall, annual direct and indirect costs 6 months before RA diagnosis were higher in patients with shorter symptom duration ( $< 6$  months).

van Jaarsveld *et al.* [12] assessed the annual direct cost related to RA during the first 6 years and identified socioeconomic and clinical determinants of these costs in an RCT conducted in the Netherlands. Patients were recruited between 1990 and 1996, and cost questionnaires were sent to those not lost to follow-up in April 1996. Mean annual direct costs by follow-up duration (year 1–6) followed a U-shaped distribution, as follows: Dutch florin (Dfl.) 14 455/patient in year 1; Dfl. 13 800/patient in year 2; Dfl. 9457/patient in year 3; Dfl. 6233/patient in year 4; Dfl. 13 005/patient in year 5; and Dfl. 11 158/patient in year 6. After adjusting for PPP and CPI 2021, total direct costs per patient (mean) in USD 2021 were \$24 094 after 1 year follow-up duration. The annual direct costs of early RA showed a U-shaped distribution over 6 years following the start of DMARDs. No analysis was performed to assess the impact of disease duration at baseline on costs in the overall cohort.

A number of studies were excluded because study participants could receive at least one DMARD before study enrolment [18–21]. Tables 3 and 4 summarize the direct and indirect costs in USD 2021, respectively, and outcomes by increasing symptom or disease duration.

## Discussion

This study highlighted several interesting findings. Firstly, two studies reported a U-shaped distribution of costs over disease duration following an RA diagnosis. Total costs were high during the initial years, slightly lower thereafter, then high again for a disease duration of  $\geq 5$  years [12] and  $> 10$  years [10]. This indicates that costs are not a linear function of disease duration.

Secondly, functional disability was a predictor of productivity costs in three studies [9, 10, 12]. In one study, patients from the highest HAQ group had the highest work disability days per year, hence the highest costs for loss of productivity [9]. This finding is highly relevant. It supports the hypothesis that aggressive early treatment can reduce costs in the longer term, because those treated earlier are less likely to have a higher level of disability, which then translates to a lower loss of productivity costs in the long term.

One study reported that the annual direct and indirect costs 6 months before diagnosis were higher in those with a symptom duration of  $< 6$  months before the start of DMARD therapy compared with those with a symptom duration

**Table 3.** Direct costs in USD 2021, symptom duration and outcomes according to increasing symptom or disease duration


| Author, country, year  | Symptom or disease duration | Symptom or disease duration (days)              | Currency in USD 2021                                  | Outcome  |
|--|-----------------------------|---|---|--|
| Verhoeven <i>et al.</i> [15]<br>The Netherlands, 2021        | Symptom duration            | Median:<br>TCZ+MTX 24.5<br>TCZ 25.5<br>MTX 27.0 | Mean:<br>TCZ + MTX 15 546<br>TCZ 18 350<br>MTX 17 840 | Direct health-care-related costs by treatment strategy group, per patient per year |
| Luurssen-Masurel <i>et al.</i> [14]<br>The Netherlands, 2021 | Symptom duration            | Median: 134                                     | Mean:<br>iMTX 3456<br>iHCQ 2839<br>iGC 4079           | Healthcare costs by treatment strategy group, patient per year                     |
| Verstappen <i>et al.</i> [10]<br>Netherlands, 2004           | Disease duration            | Mean: 329                                       | Mean: 14 613<br>Median: 8159                          | Total direct costs per patient per year  |
| van Jaarsveld <i>et al.</i> [12]<br>The Netherlands, 1998    | Disease duration            | Inclusion criteria: 0–365                       | Mean: 16 472  | Direct medical cost per person per year, per patient                               |
| Syngle <i>et al.</i> [16]<br>India, 2017                     | Disease duration            | Mean: 2117                                      | Average: 1008   | Direct medical cost per patient per year   |

iGC: initial treatment strategy with glucocorticoids; iHCQ: initial treatment strategy with HCQ; iMTX: initial treatment strategy with MTX; TCZ: tocilizumab.

**Table 4.** Indirect costs in USD 2021, symptom duration and outcomes according to increasing symptom or disease duration

| Author, country, year                                       | Symptom or disease duration  | Symptom or disease duration (days)              | Currency in USD 2021   | Outcome   |
|---|--|---|--|---|
| Merkesdal <i>et al.</i> [11]<br>Germany, 2001               | Disease duration   | Mean: 213                                       | Mean:<br>Time 0–time 2: 20 180<br>Time 2–time 3: 15 865<br>Time 0–time 3: 18 848   | Loss of productivity costs: total sick leave, work disability and other work loss                                   |
| Luursen-Masurel <i>et al.</i> [14]<br>The Netherlands, 2021 | Symptom duration   | Median: 134                                     | Mean:<br>iMTX 11 031<br>iHCQ 12 149<br>iGC 9967  | Total productivity costs by treatment strategy group  |
| Verhoeven <i>et al.</i> [15]<br>The Netherlands, 2021       | Symptom duration   | Median:<br>TCZ+MTX 24.5<br>TCZ 25.5<br>MTX 27.0 | Human capital approach:<br>TCZ + MTX 17 076<br>TCZ 14 272<br>MTX 16 566<br>Friction cost approach:<br>TCZ + MTX 6371<br>TCZ 5862<br>MTX 6371 | Loss of productivity costs loss using human capital approach and friction cost approach by treatment strategy group |
| Puolakka <i>et al.</i> [9]<br>Finland, 2009                 | Disease duration<br>HAQ group 1<br>HAQ group 2<br>HAQ group 3<br>HAQ group 4 | Mean:<br>335<br>243<br>243<br>304               | Mean:<br>HCA 736<br>FCA 590<br>HCA 4523<br>FCA 2275<br>HCA 20 191<br>FCA 4101<br>HCA 40 116<br>FCA 6125                                      | Loss of productivity cost by human capital approach and friction cost approach by HAQ group                         |

iGC: initial treatment strategy with glucocorticoids; iHCQ: initial treatment strategy with HCQ; iMTX: initial treatment strategy with MTX; TCZ: tocilizumab; time 0: onset of disease; time 2: reassessment at 12 months following baseline assessment; time 3: reassessment at 24 months following baseline assessment.



**Figure 2.** Timing and duration for which the respective health economic outcomes are reported and the symptom duration before DMARD initiation. The blue arrows indicate the symptom/disease duration reported in each study. The green arrows indicate the timing and duration of health economic outcomes reported in each study. Puolakka *et al.* [9] reported six groups of patients stratified by HAQ groups. <sup>a</sup>Verstappen *et al.* [10] reported four groups of patients based on disease duration (defined as the time elapsed from study recruitment). Van Jaarsveld *et al.* [12] reported six groups of patients based on disease duration (defined as the time elapsed from study recruitment). <sup>b</sup>Kuijper *et al.* [8] and Newhall-Perry *et al.* [13] reported disease duration at the time of study enrolment. FCA: friction cost approach; HCA: human capital approach

≥6 months [13]. In contrast, another study reported that longer symptom duration before diagnosis (>180 days) was associated with lower health-care utilization over the first year of diagnosis [8]. The contrasting trend between the two studies can be explained by the difference in the timing of when the health economic outcomes were recorded. Health-care utilization over the first year following RA diagnosis was recorded in the latter study; however, costs before RA diagnosis were recorded in the former study.

In this review, we could not delineate the aggregated-level data related to the relationship between symptom/disease/diagnosis duration and cost categories owing to the heterogeneity of the following factors: timing and duration of data collection regarding resources and costs; type of resources/cost-categories reported; and inconsistency in reported disease, symptom or diagnosis duration (Fig. 2). Moreover, the duration of cost data recorded (i.e. 6 months *vs* 6 years) also differed across studies (Fig. 2).

Before the era of early treatment, RA costs were related to established disease. Patients had more frequent hospitalization [22] and more frequent joint replacement than the

general population [23], and a majority were unable to work. The early introduction of biological and targeted synthetic DMARD therapy has resulted in high costs of medications [23]. However, high drug cost can potentially be offset in the long term, at least in part, by reducing disease-related costs (e.g. loss of productivity owing to work disability, hospitalization and joint surgery). In addition, patients treated early were more likely to achieve DMARD-free remission [1]. Therefore, this would reduce the proportion of patients on long-term DMARDs [24].

Clear definitions of RA onset and duration have been proposed [25], because reporting in clinical studies is currently heterogeneous [25]. RA duration can be timed from the following points: onset of RA symptoms; onset of joint swelling; when RA classification criteria were first fulfilled; or the time of RA diagnosis. Using a clearly defined onset will allow meaningful comparison of clinical outcomes and health economic outcomes between early RA studies.

A strength of this review is the broad range of health economic outcomes and types of health economic studies that were included. Both direct and indirect costs, and cost-of-

illness and cost-utility studies were within the scope of this review. Observational and clinical trials were also included.

However, only a small number of studies fulfilled our strict inclusion criteria. In addition, studies that enrolled patients who had recently been treated with DMARDs before study recruitment were not included in this review. Furthermore, meta-analyses/regression were not possible owing to the different types of health economic outcomes reported.

This review is the first to highlight a vital evidence gap in early arthritis: what is the financial consequence of diagnosing and treating patients with RA during the early disease phase? Health economic modelling with carefully defined symptom duration, resource utilization, treatment and long-term productivity costs is vital to address this important question.

## Supplementary material

Supplementary material is available at *Rheumatology Advances in Practice* online.

## Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

## Funding

This work was supported by the National Institute for Health and Care Research (NIHR)/Wellcome Trust Clinical Research Facility and NIHR Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust. This work was also supported by the Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (Arthritis Research UK grant number 20298), the European Community's Collaborative project FP7-HEALTH-F2-2012-305549 'Euro-TEAM' and Versus Arthritis Research into Inflammatory Arthritis Centre (Versus Arthritis UK grant number 22072). The views expressed are those of the author(s) and not necessarily those of the MRC or Arthritis Research UK. I.S. is supported by the University of Birmingham via a clinical lectureship. K.R. and A.F. are supported by the NIHR Birmingham Biomedical Research Centre.

**Disclosure statement:** K.R.: Personal fees from Abbvie and Sanofi; grant/research support from Bristol Myers Squibb. A.F.: Personal fees from Abbvie, Roche and Janssen; grant/research support from Roche, UCB, Mestag, GSK and Janssen. The remaining authors have declared no conflicts of interest.

## Acknowledgements

We wish to thank Stephen Yates and Jennifer Manders, University Hospitals Birmingham Foundation NHS Trust, who conducted the systematic search for this review.

## References

- van der Linden MP, le Cessie S, Raza K *et al.* Long-term impact of delay in assessment of patients with early arthritis. *Arthritis Rheum* 2010;62:3537–46.
- Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. *J Rheumatol* 1998;25:2108–17.
- Puolakka K, Kautiainen H, Mottonen T *et al.*; FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. *Arthritis Rheum* 2005;52:36–41.
- von Elm E, Altman DG, Egger M *et al.*; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370:1453–7.
- Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. *BMJ* 1996;313:275–83.
- OECD, Purchasing power parities (PPP) (indicator). 2022. doi: 10.1787/1290ee5a-en. <https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm> (25 March 2022, date last accessed).
- OECD, Inflation (CPI) (indicator). 2022. doi: 10.1787/ee82e6e-en. <https://data.oecd.org/price/inflation-cpi.htm#indicator-chart> (25 March 2022, date last accessed).
- Kuijper TM, Luime JJ, Alves C *et al.* Quality of life and health care use in patients with arthralgias without synovitis compared with patients diagnosed with early rheumatoid arthritis: data from an early arthritis cohort. *Arthritis Care Res (Hoboken)* 2014;66:379–86.
- Puolakka K, Kautiainen H, Mottonen T *et al.* Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis. *Scand J Rheumatol* 2009;38:96–103.
- Verstappen SM, Verkleij H, Bijlsma JW *et al.* Determinants of direct costs in Dutch rheumatoid arthritis patients. *Ann Rheum Dis* 2004;63:817–24.
- Merkesdal S, Ruof J, Schöffski O *et al.* Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. *Arthritis Rheum* 2001;44:528–34.
- van Jaarsveld CH, Jacobs JW, Schrijvers AJ *et al.* Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. *Br J Rheumatol* 1998;37:837–47.
- Newhall-Perry K, Law NJ, Ramos B *et al.* Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. *J Rheumatol* 2000;27:1156–63.
- Luursen-Masurel N, van Mulligen E, Weel AEAM, Hazes JMW, de Jong PHP; tREACH Group Investigators. Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients. *Rheumatology (Oxford)* 2021;60:5765–74.
- Verhoeven MMA, Tekstra J, van Laar JM *et al.* Effect on costs and quality-adjusted life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. *J Rheumatol* 2021;48:495–503.
- Syngle A, Kaur S, Verma I, Syngle T, Syngle V. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis. *Clin Rheumatol* 2017;36:1715–20.
- Perspective [online]. Definition of perspective. York: York Health Economics Consortium 2016. <https://yhcc.co.uk/glossary/perspective/> (4 April 2022, date last accessed).
- Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. *Combinatietherapie Bij Reumatoide Artritis*. *Br J Rheumatol* 1998;37:1102–9.
- Ter Wee MM, Coupe VM, den Uyl D *et al.* Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. *RMD Open* 2017;3:e000502.
- Korthals-de Bos I, Van Tulder M, Boers M *et al.* Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. *J Rheumatol* 2004;31:1709–16.



21. Pazmino S, Boonen A, Stouten V *et al.* Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. *Ann Rheum Dis* 2020;79: 556–65.
22. Hsieh P-H, Wu O, Geue C *et al.* Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. *Ann Rheum Dis* 2020;79:771–7.
23. Kalkan A, Hallert E, Bernfort L, Husberg M, Carlsson P. Costs of rheumatoid arthritis during the period 1990–2010: a register-based cost-of-illness study in Sweden. *Rheumatology (Oxford)* 2014;53: 153–60.
24. van Nies JA, Krabben A, Schoones JW *et al.* What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. *Ann Rheum Dis* 2014;73:861–70.
25. Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. *Ann Rheum Dis* 2012;71:1921–3.

# A 2nd generation, JAK1 preferential inhibitor for moderate to severe RA<sup>1-6</sup>

While 1st generation JAK inhibitors are relatively non-selective,<sup>2-6</sup> JYSELECA has over 5x greater potency for JAK1 over JAK2/3 and TYK2<sup>1\*</sup>

Balancing sustained efficacy<sup>7-11</sup> with acceptable tolerability<sup>1,12</sup>

Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs.<sup>1</sup> May be used as monotherapy or in combination with methotrexate.<sup>1</sup>

\*From biochemical assays, the clinical relevance of which is uncertain. JAK, Janus kinase; RA, rheumatoid arthritis; TYK, tyrosine kinase.

Learn more at  
[strengthofbalance.co.uk](http://strengthofbalance.co.uk)

Refer to Summary of Product Characteristics (SmPC) before prescribing, and for full prescribing information.

**JYSELECA**<sup>®</sup> filgotinib 100 mg or 200 mg film-coated tablets.

**Indication:** Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX). **Dosage: Adults:** 200 mg once daily. Taken orally with/without food. It is recommended that tablets are swallowed whole. **Laboratory Monitoring:** Refer to the SmPC for information regarding laboratory monitoring and dose initiation or interruption. **Elderly:** A starting dose of 100 mg once daily is recommended for patients aged 75 years and older as clinical experience is limited. **Renal impairment:** No dose adjustment required in patients with estimated creatinine clearance (CrCl)  $\geq$  60 mL/min. A dose of 100 mg of filgotinib once daily is recommended for patients with moderate or severe renal impairment (CrCl 15 to < 60 mL/min). Not recommended in patients with CrCl < 15 mL/min. **Hepatic impairment:** Mild/moderate hepatic impairment: no dose adjustment required. Severe hepatic impairment: not recommended. **Children (< 18 years):** Safety and efficacy not yet established. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Active tuberculosis (TB) or active serious infections. **Pregnancy/Warnings/Precautions:** See SmPC for full information. **Immunosuppression:** Combination use, with immunosuppressants e.g., ciclosporin, tacrolimus, biologics or other Janus kinase (JAK) inhibitors is not recommended as a risk of additive immunosuppression cannot be excluded. **Infections:** Infections, including serious infections such as pneumonia and opportunistic infections e.g. tuberculosis (TB), oesophageal candidiasis, and cryptococcosis have been reported. Risk benefit should be assessed prior to initiating in patients with risk factors for infections (see SmPC). Patients should be closely monitored for the development of signs and symptoms of infections during and after filgotinib treatment. Treatment should be interrupted if the patient

is not responding to antimicrobial therapy, until infection is controlled. There is a higher incidence of serious infections in the elderly aged 75 years and older, caution should be used when treating this population. **Tuberculosis:** Patients should be screened for TB before initiating filgotinib, and filgotinib should not be administered to patients with active TB. **Viral reactivation:** Cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies (see SmPC). If a patient develops herpes zoster filgotinib treatment should be temporarily interrupted until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should be performed. **Malignancy:** Immunomodulatory medicinal products may increase the risk of malignancies. Malignancies were observed in clinical studies (see SmPC). **Fertility:** In animal studies, decreased fertility, impaired spermatogenesis, and histopathological effects on male reproductive organs were observed (see SmPC). The potential effect of filgotinib on sperm production and male fertility in humans is currently unknown. **Haematological abnormalities:** Do not start therapy, or temporarily stop, if Absolute Neutrophil Count (ANC) <  $1 \times 10^9$  cells/L, ALC <  $0.5 \times 10^9$  cells/L or haemoglobin < 8 g/dL. Temporarily stop therapy if these values are observed during routine patient management. **Vaccinations:** Use of live vaccines during, or immediately prior to, filgotinib treatment is not recommended. **Lipids:** Treatment with filgotinib was associated with dose dependent increases in lipid parameters, including total cholesterol, and high-density lipoprotein (HDL) levels, while low density lipoprotein (LDL) levels were slightly increased (see SmPC). **Cardiovascular risk:** Rheumatoid arthritis patients have an increased risk for cardiovascular disorders. Patients should have risk factors (e.g., hypertension, hyperlipidaemia) managed as part of usual standard of care. **Venous thromboembolism:** Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving JAK inhibitors including filgotinib. Caution should be used in patients with risk factors for DVT/PE, such as older age, obesity, a medical history of DVT/PE, or patients undergoing surgery, and prolonged

immobilisation. **Lactose content:** Contains lactose; patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take filgotinib. **Pregnancy/Lactation:** Filgotinib is contraindicated in pregnancy. Filgotinib should not be used during breast-feeding. Women of childbearing potential must use effective contraception during and for at least 1 week after cessation of treatment. **Driving/Using machinery:** No or negligible influence, however dizziness has been reported. **Side effects:** See SmPC for full information. **Common ( $\geq 1/100$  to < 1/10):** nausea, upper respiratory tract infection, urinary tract infection and dizziness. **Uncommon ( $\geq 1/1000$  to < 1/100):** herpes zoster, pneumonia, neutropenia, hypercholesterolaemia and blood creatine phosphokinase increase. **Serious side effects:** See SmPC for full information. **Legal category:** POM. **Pack:** 30 film-coated tablets/bottle. **Price:** UK Basic NHS cost: £863.10. **Marketing authorisation number(s):** Great Britain Jyseleca 100mg film-coated tablets PLGB 42147/0001 Jyseleca 200mg film-coated tablets PLGB 42147/0002 Northern Ireland Jyseleca 100mg film-coated tablets EU/1/20/1480/001 EU/1/20/1480/002 Jyseleca 200mg film-coated tablets EU/1/20/1480/003 EU/1/20/1480/004. **Further information:** Galapagos UK, Belmont House, 148 Belmont Road, Uxbridge UB8 1QS, United Kingdom 00800 7878 1345 [medicalinfo@glog.com](mailto:medicalinfo@glog.com) Jyseleca<sup>®</sup> is a trademark. **Date of Preparation:** January 2022 UK-RA-FIL-202201-00019

∇ Additional monitoring required

Adverse events should be reported.

For Great Britain and Northern Ireland, reporting forms and information can be found at [yellowcard.mhra.gov.uk](http://yellowcard.mhra.gov.uk) or via the Yellow Card app (download from the Apple App Store or Google Play Store).

Adverse events should also be reported to Galapagos via email to [DrugSafety.UK.Ireland@glog.com](mailto:DrugSafety.UK.Ireland@glog.com) or 00800 7878 1345

**References:** 1. JYSELECA SPC. Available at: [www.medicines.org.uk](http://www.medicines.org.uk). Last accessed: June 2022. 2. Angelini J, et al. *Biomolecules* 2020;10(7):E1002. 3. Banerjee S, et al. *Drugs* 2017;77:521-546. 4. O'Shea JJ, et al. *Nat Rev Rheumatol* 2013;9(3):173-182. 5. Traves PG, et al. *Ann Rheum Dis* 2021;01-11. 6. McInnes IB, et al. *Arthr Res Ther* 2019;21:183. 7. Combe B, et al. *Ann Rheum Dis* 2021;doi:10.1136/annrheumdis-2020-219214. 8. Genovese MC, et al. *JAMA* 2019;322(4):315-325. 9. Westhovens R, et al. *Ann Rheum Dis* 2021;doi:10.1136/annrheumdis-2020-219213. 10. Combe B, et al. *Arthritis Rheumatol* 2021;73(suppl 10). <https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-filgotinib-treatment-in-an-ongoing-long-term-extension-trial-of-rt-patients-with-inadequate-response-to-mtx-initially-treated-with-filgotinib-or-adalimumab-during-th/>. Last accessed: June 2022. 11. Buch MH, et al. *Arthritis Rheumatol* 2021;73(suppl 10). <https://acrabstracts.org/abstract/clinical-outcomes-up-to-week-48-of-ongoing-filgotinib-ra-long-term-extension-trial-of-biologic-dmard-inadequate-responders-initially-on-filgotinib-or- placebo-in-a-phase-3-trial/>. Last accessed: June 2022. 12. Winthrop K, et al. *Arthritis Rheumatol* 2021;73(suppl 10). Available at: <https://acrabstracts.org/abstract/integrated-safety-analysis-update-for-filgotinib-in-patients-with-moderately-to-severely-active-rheumatoid-arthritis-receiving-treatment-over-a-median-of-2-2-years/>. Last accessed: June 2022.

## Galápagos

June 2022 GB-RA-JY-202205-00033

JYSELECA, GALAPAGOS and the JYSELECA and GALAPAGOS logos are registered trademarks of Galapagos NV. © 2022 Galapagos NV. All rights reserved.